Marimastat

Drug Profile

Marimastat

Alternative Names: BB 2516; TA 2516

Latest Information Update: 22 Mar 2004

Price : $50

At a glance

  • Originator Vernalis
  • Developer Schering-Plough; Tanabe Seiyaku; Vernalis
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Glioma; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 22 Mar 2004 Discontinued - Phase-II for Gastric cancer in Japan (PO)
  • 22 Mar 2004 Discontinued - Phase-II for Head and neck cancer in USA (PO)
  • 22 Mar 2004 Discontinued - Phase-II for Lung cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top